Non-Alcoholic Fatty Liver Disease (NAFLD) is a common, yet complex, hepatic disorder that is emerging as a global health burden. It is a spectrum of diseases ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Understanding its causes, diagnostic methods, and modern therapeutic approaches is vital for effective patient management.
Although the pathogenesis of NAFLD is multifactorial, insulin resistance and metabolic syndrome are considered central to its development. Other factors include genetics, diet, gut microbiota, and sedentary lifestyle. NAFLD is often associated with obesity, type 2 diabetes, and dyslipidemia.
NAFLD is often silent, discovered incidentally during routine blood tests or imaging. However, a definitive diagnosis requires a liver biopsy, the gold standard for assessing liver histology. Non-invasive diagnostic strategies, such as ultrasound, elastography, and serum biomarkers, are also used to estimate liver fat content and fibrosis.
Current therapeutic strategies for NAFLD focus on lifestyle modifications, including diet and exercise. Pharmacological interventions are reserved for patients with NASH and significant fibrosis. These include insulin sensitizers, antioxidants, and lipid-lowering agents. Emerging therapies, such as FXR agonists and GLP-1R agonists, are showing promise in clinical trials.
NAFLD is a complex disease with multifactorial causes and a broad spectrum of clinical manifestations. Early identification and intervention are crucial to prevent progression to more severe liver disease. While lifestyle modification remains the cornerstone of management, advances in pharmacological therapies offer hope for more effective treatment options in the future. As our understanding of NAFLD continues to evolve, so too must our strategies for diagnosis and treatment.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation